{"items": "10", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China - LakeShore Biopharma  ( NASDAQ:LSB ) ", "url": "https://www.benzinga.com/pressreleases/24/12/g42476047/lakeshore-biopharma-provides-update-on-ongoing-criminal-investigation-involving-former-chairman-in", "time_published": "20241213T005707", "authors": ["Globe Newswire"], "summary": "BEIJING, Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- LakeShore Biopharma Co., Ltd.", "banner_image": "https://ml.globenewswire.com/media/7cfb3eb6-57bb-4dca-8761-63b601086d33/small/20241012105327-png.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.714479"}], "overall_sentiment_score": 0.112766, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LSB", "relevance_score": "0.510213", "ticker_sentiment_score": "0.113215", "ticker_sentiment_label": "Neutral"}]}, {"title": "LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China", "url": "https://www.globenewswire.com/news-release/2024/12/13/2996586/0/en/LakeShore-Biopharma-Provides-Update-on-Ongoing-Criminal-Investigation-Involving-Former-Chairman-in-China.html", "time_published": "20241213T005700", "authors": ["Ltd", "LakeShore Biopharma Co."], "summary": "BEIJING, Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- LakeShore Biopharma Co., Ltd. ( Nasdaq: LSB ) ( \"LakeShore Biopharma\" or the \"Company\" ) , a leading global biopharmaceutical company focused on the innovation and production of vaccines and therapeutic biologics for infectious diseases and cancer, ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/7cfb3eb6-57bb-4dca-8761-63b601086d33", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.084394, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LSB", "relevance_score": "0.476132", "ticker_sentiment_score": "0.111726", "ticker_sentiment_label": "Neutral"}]}, {"title": "LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan - LakeShore Biopharma  ( NASDAQ:LSB ) ", "url": "https://www.benzinga.com/pressreleases/24/11/g41805014/lakeshore-biopharma-initiates-biologics-license-application-of-pika-rabies-vaccine-to-the-drug-reg", "time_published": "20241107T130000", "authors": ["Globe Newswire"], "summary": "GAITHERSBURG, Md., Nov. 07, 2024 ( GLOBE NEWSWIRE ) -- LakeShore Biopharma Co., Ltd LSB ( \"LakeShore Biopharma\" or the \"Company\" ) , a global leader in the discovery, development, manufacturing, and delivery of next-generation vaccines and therapeutic biologics for infectious diseases and ...", "banner_image": "https://ml.globenewswire.com/media/7cfb3eb6-57bb-4dca-8761-63b601086d33/small/20241012105327-png.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.714479"}], "overall_sentiment_score": 0.108113, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LSB", "relevance_score": "0.477901", "ticker_sentiment_score": "0.202141", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Catalent  ( CTLT )  Tops Q4 Earnings and Revenue Estimates", "url": "https://www.zacks.com/stock/news/2328747/catalent-ctlt-tops-q4-earnings-and-revenue-estimates", "time_published": "20240829T124502", "authors": ["Zacks Equity Research"], "summary": "Catalent (CTLT) delivered earnings and revenue surprises of 41.30% and 5.37%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default317.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.999981"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.162225, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CTLT", "relevance_score": "0.400265", "ticker_sentiment_score": "0.208042", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LSB", "relevance_score": "0.20698", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sol-Gel Technologies Ltd.  ( SLGL )  Surpasses Q2 Earnings and Revenue Estimates", "url": "https://www.zacks.com/stock/news/2322848/sol-gel-technologies-ltd-slgl-surpasses-q2-earnings-and-revenue-estimates", "time_published": "20240816T121004", "authors": ["Zacks Equity Research"], "summary": "SolGel Technologies (SLGL) delivered earnings and revenue surprises of 135% and 414.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default33.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.999892"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.117098, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SLGL", "relevance_score": "0.136499", "ticker_sentiment_score": "-0.024601", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSB", "relevance_score": "0.2035", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Invivyd, Inc.  ( IVVD )  Reports Q2 Loss, Lags Revenue Estimates", "url": "https://www.zacks.com/stock/news/2321866/invivyd-inc-ivvd-reports-q2-loss-lags-revenue-estimates", "time_published": "20240814T131004", "authors": ["Zacks Equity Research"], "summary": "Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -8.11% and 53.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default307.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999336"}, {"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.10564, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IVVD", "relevance_score": "0.411176", "ticker_sentiment_score": "0.050387", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSB", "relevance_score": "0.213048", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Roivant Sciences Ltd.  ( ROIV )  Reports Q1 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2318911/roivant-sciences-ltd-roiv-reports-q1-loss-tops-revenue-estimates", "time_published": "20240808T122012", "authors": ["Zacks Equity Research"], "summary": "Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 14.29% and 72.76%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default355.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.110027, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ROIV", "relevance_score": "0.136888", "ticker_sentiment_score": "-0.063476", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSB", "relevance_score": "0.204072", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "news", "url": "https://www.prnewswire.com/news/lakeshore-biopharma-co.%2C-ltd/", "time_published": "20240705T110515", "authors": [], "summary": "LakeShore Biopharma Co., Ltd ( Nasdaq: LSB ) ( \"LakeShore Biopharma\" or the \"Company\" ) , a global biopharmaceutical company dedicated to discovering,... Join PR Newswire for Journalists to access all of the free services designated to make your job easier.", "banner_image": "https://www.prnewswire.com/content/dam/prnewswire/common/JournalistsBloggers.jpg", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.531624, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "LSB", "relevance_score": "0.982136", "ticker_sentiment_score": "0.636522", "ticker_sentiment_label": "Bullish"}]}, {"title": "LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition", "url": "https://www.prnewswire.com/apac/news-releases/lakeshore-biopharma-to-hold-an-extraordinary-general-meeting-on-july-25-2024-pursuant-to-shareholders-requisition-302189971.html", "time_published": "20240705T110000", "authors": ["Ltd", "LakeShore Biopharma Co."], "summary": "LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2421456/LakeShore_Bio_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.795202"}], "overall_sentiment_score": 0.122979, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LSB", "relevance_score": "0.511734", "ticker_sentiment_score": "0.141594", "ticker_sentiment_label": "Neutral"}]}, {"title": "LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition", "url": "https://www.prnewswire.com/news-releases/lakeshore-biopharma-to-hold-an-extraordinary-general-meeting-on-july-25-2024-pursuant-to-shareholders-requisition-302189967.html", "time_published": "20240705T110000", "authors": ["LakeShore Biopharma Co.", "Ltd"], "summary": "LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2421456/LakeShore_Bio_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.795202"}], "overall_sentiment_score": 0.122979, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LSB", "relevance_score": "0.511734", "ticker_sentiment_score": "0.141594", "ticker_sentiment_label": "Neutral"}]}]}